First Horizon Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

First Horizon Advisors’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-292	Closed	-$8K	–	1709
2021 Q4	$8K	Hold	292	–	–	﹤0.01%	1581
2021 Q3	$9K	Hold	292	–	–	﹤0.01%	1557
2021 Q2	$11K	Buy	+292	New	+$11.4K	﹤0.01%	1304

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

First Horizon Advisors's ADPT Position: Q1 2022 in Review

First Horizon Advisors sold out of Adaptive Biotechnologies (ADPT) in Q1 2022, closing a stake of 292 shares — an estimated $8K sold.

First Horizon Advisors first reported a position in ADPT in Q2 2021 and held it in 3 quarters. The position peaked at $11K in Q2 2021. 221 funds tracked by Wall St. Rank hold ADPT as of Q1 2022.

First Horizon Advisors reported no remaining Adaptive Biotechnologies position as of Q1 2022 after selling out during the quarter.
First Horizon Advisors sold 292 Adaptive Biotechnologies shares in Q1 2022, an estimated $8K.
First Horizon Advisors first reported a position in Adaptive Biotechnologies in Q2 2021 and held it in 3 quarters.
First Horizon Advisors's Adaptive Biotechnologies position peaked at $11K in Q2 2021.
221 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2022.

Based on First Horizon Advisors's 13F filing for Q1 2022, filed 10 May 2022.